Ikarian Capital, LLC Chimerix Inc Transaction History

Ikarian Capital, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.34 - $5.34 $536,000 - $2.14 Million	-400,000 Reduced 47.55%	441,203 $917,000
Q1 2022 May 13, 2022	BUY	$4.58 - $6.8 $209,731 - $311,392	45,793 Added 5.76%	841,203 $3.85 Million
Q4 2021 Feb 14, 2022	SELL	$5.23 - $7.18 $30,846 - $42,347	-5,898 Reduced 0.74%	795,410 $5.11 Million
Q3 2021 Nov 15, 2021	SELL	$5.94 - $8.75 $4.6 Million - $6.78 Million	-774,608 Reduced 49.15%	801,308 $4.96 Million
Q2 2021 Aug 16, 2021	SELL	$7.54 - $9.79 $162,848 - $211,444	-21,598 Reduced 1.35%	1,575,916 $12.6 Million
Q1 2021 May 17, 2021	BUY	$4.76 - $11.25 $1.74 Million - $4.11 Million	365,001 Added 29.61%	1,597,514 $15.4 Million
Q4 2020 Feb 12, 2021	SELL	$2.43 - $5.42 $319,620 - $712,898	-131,531 Reduced 9.64%	1,232,513 $5.95 Million
Q3 2020 Nov 16, 2020	BUY	$2.3 - $3.72 $3.14 Million - $5.07 Million	1,364,044 New	1,364,044 $3.4 Million
Q2 2020 Aug 14, 2020	SELL	$1.33 - $3.63 $276,983 - $755,976	-208,258 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.27 - $2.33 $44,879 - $82,337	35,338 Added 20.44%	208,258 $300,000
Q4 2019 Jan 31, 2020	BUY	$1.3 - $2.72 $224,796 - $470,342	172,920 New	172,920 $351,000

36.8M

72.2K

169K

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $85M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.